Related Experiment Video
Updated: Aug 11, 2026

Detection of Functional Matrix Metalloproteinases by Zymography
Published on: November 9, 2010
Matrix metalloproteinase inhibitors
Nithya Ramnath1, Patrick J Creaven
1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Abstract:
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that are associated with the tumorigenic process. MMPs degrade the extracellular matrix, promoting tumor invasion and metastasis. They also regulate host defense mechanisms and normal cell function; blocking all MMPs may not lead to a positive therapeutic outcome. Most clinical trials of MMP inhibitors (MMPIs) have yielded disappointing results, perhaps due to inappropriate study design or tumor staging, or to lack of selectivity. Positive results have been seen in gastric cancer with marimastat and in Kaposi's sarcoma with metastat. This review summarizes the current status of MMPIs.
Insights
Matrix metalloproteinases (MMPs) are key in cancer progression. While MMP inhibitors show promise, clinical trials have had mixed results, necessitating further research into their therapeutic potential.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs) are enzymes crucial for extracellular matrix degradation.
- MMPs play a significant role in tumor invasion, metastasis, and regulating cellular functions.
- Dysregulation of MMPs is implicated in various pathological conditions, including cancer.
Purpose of the Study:
- To review the current status of matrix metalloproteinase inhibitors (MMPIs) in cancer therapy.
- To discuss the challenges and potential reasons for the limited success of MMPI clinical trials.
- To highlight specific examples of MMPIs with positive outcomes in certain cancers.
Main Methods:
- Literature review of preclinical and clinical studies on MMPs and MMPIs.
- Analysis of factors contributing to the efficacy and limitations of MMPIs.
- Examination of case studies involving marimastat and metastat.
Main Results:
- MMPs are involved in tumor invasion and metastasis by degrading the extracellular matrix.
- Most clinical trials of broad-spectrum MMP inhibitors have yielded disappointing results.
- Selective MMPIs have shown positive outcomes in specific cancers like gastric cancer and Kaposi's sarcoma.
Conclusions:
- Targeting MMPs remains a complex therapeutic strategy due to their diverse roles.
- Lack of selectivity and inappropriate trial design may explain the limited success of MMPIs.
- Further research is needed to optimize MMPIs for effective cancer treatment.
More Related Videos
Related Concept Videos
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
MicroRNAs
Role of Matrix Metalloproteases in Degradation of ECM
A...

